
    
      A total of approximately 30 patients with MTC will be enrolled. The patients will undergo a 3
      weeks-on and 1week-off treatment scheme with HA121-28 tablets 600 mg orally once daily in the
      28-day cycle until disease progression or intolerable toxic reaction, whichever occurs first.
      During the administration of HA121-28 tablets, vital signs, physical examination, ECOG
      performance status, hematology and chemistry test, ECG, adverse events and concomitant drugs
      will be evaluated every four weeks, calcitonin and pregnancy test will be performed every 8
      weeks. CT for tumor assessment will be performed every 8 weeks for the first year, and every
      12 weeks thereafter.
    
  